Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity.
Kirchhammer N, Trefny MP, Natoli M, Brücher D, Smith SN, Werner F, Koch V, Schreiner D, Bartoszek E, Buchi M, Schmid M, Breu D, Hartmann KP, Zaytseva P, Thommen DS, Läubli H, Böttcher JP, Stanczak MA, Kashyap AS, Plückthun A, Zippelius A. Kirchhammer N, et al. Among authors: natoli m. Sci Transl Med. 2022 Jul 13;14(653):eabm9043. doi: 10.1126/scitranslmed.abm9043. Epub 2022 Jul 13. Sci Transl Med. 2022. PMID: 35857639 Free article.
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
Natoli M, Hatje K, Gulati P, Junker F, Herzig P, Jiang Z, Davydov II, Germann M, Trüb M, Marbach D, Zwick A, Weber P, Seeber S, Wiese M, Lardinois D, Heinzelmann-Schwarz V, Rosenberg R, Tietze L, Mertz KD, Umaña P, Klein C, Codarri-Deak L, Kao H, Zippelius A. Natoli M, et al. J Immunother Cancer. 2022 Nov;10(11):e005548. doi: 10.1136/jitc-2022-005548. J Immunother Cancer. 2022. PMID: 36319064 Free PMC article.
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy.
Trefny MP, Kirchhammer N, Auf der Maur P, Natoli M, Schmid D, Germann M, Fernandez Rodriguez L, Herzig P, Lötscher J, Akrami M, Stinchcombe JC, Stanczak MA, Zingg A, Buchi M, Roux J, Marone R, Don L, Lardinois D, Wiese M, Jeker LT, Bentires-Alj M, Rossy J, Thommen DS, Griffiths GM, Läubli H, Hess C, Zippelius A. Trefny MP, et al. Among authors: natoli m. Nat Commun. 2023 Feb 2;14(1):86. doi: 10.1038/s41467-022-35583-w. Nat Commun. 2023. PMID: 36732507 Free PMC article.
Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P, Spear S, Mirza H, Garner I, McGarry L, Grundland-Freile F, Cheng Z, Ennis DP, Iyer N, McNamara S, Natoli M, Mason S, Blyth K, Adams PD, Roxburgh P, Fuchter MJ, Brown B, McNeish IA. Spiliopoulou P, et al. Among authors: natoli m. Mol Cancer Ther. 2022 Apr 1;21(4):522-534. doi: 10.1158/1535-7163.MCT-21-0743. Mol Cancer Ther. 2022. PMID: 35131874 Free PMC article.
Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
Wahba J, Natoli M, Whilding LM, Parente-Pereira AC, Jung Y, Zona S, Lam EW, Smith JR, Maher J, Ghaem-Maghami S. Wahba J, et al. Among authors: natoli m. Cancer Immunol Immunother. 2018 Nov;67(11):1753-1765. doi: 10.1007/s00262-018-2199-8. Epub 2018 Aug 24. Cancer Immunol Immunother. 2018. PMID: 30167862 Free PMC article.
73 results